Take Ltd
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services[1]
- Market Cap ₹ 203 Cr.
- Current Price ₹ 13.7
- High / Low ₹ 50.1 / 9.83
- Stock P/E 23.3
- Book Value ₹ 2.14
- Dividend Yield 0.00 %
- ROCE 11.6 %
- ROE 9.99 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 6.39 times its book value
- Company has a low return on equity of -74.4% over last 3 years.
- Earnings include an other income of Rs.8.41 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology
Part of BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.89 | 23.57 | 18.84 | 2.44 | 21.96 | 2.47 | 10.72 | 18.00 | 56.23 | 5.42 | 0.90 | 0.00 | 26.29 | |
| Sales growth | -0.50% | -8.96% | -20.07% | -87.05% | +800.00% | -88.75% | +334.01% | +67.91% | +212.39% | -90.36% | -83.39% | -100.00% | +65,825.00% |
| 24.45 | 18.36 | 22.44 | 18.64 | 35.83 | 19.38 | 17.59 | 31.35 | 53.37 | 14.94 | 2.90 | 3.45 | 26.01 | |
| Operating Profit | 1.44 | 5.21 | -3.60 | -16.20 | -13.87 | -16.91 | -6.87 | -13.35 | 2.86 | -9.52 | -2.00 | -3.45 | 0.28 |
| OPM % | 5.56% | 22.10% | -19.11% | -663.93% | -63.16% | -684.62% | -64.09% | -74.17% | 5.09% | -175.65% | -222.22% | 1.07% | |
| 12.80 | 15.64 | 22.05 | 32.81 | 34.35 | 26.08 | 15.32 | -459.92 | 3.63 | -192.27 | -66.94 | 6.63 | 8.41 | |
| Interest | 0.11 | 0.40 | 3.08 | 1.07 | 0.17 | 0.49 | 0.36 | 0.30 | 0.68 | 0.74 | 0.75 | 0.29 | 0.00 |
| Depreciation | 0.74 | 0.19 | 0.80 | 0.80 | 0.80 | 1.74 | 1.57 | 1.23 | 1.11 | 0.72 | 0.04 | 0.01 | 0.00 |
| Profit before tax | 13.39 | 20.26 | 14.57 | 14.74 | 19.51 | 6.94 | 6.52 | -474.80 | 4.70 | -203.25 | -69.73 | 2.88 | 8.69 |
| Tax % | 15.46% | 10.02% | 1.10% | -3.39% | 10.81% | -11.38% | -19.63% | 0.50% | 8.72% | 1.97% | 0.00% | 5.56% | |
| 11.32 | 18.23 | 14.42 | 15.25 | 17.40 | 7.74 | 7.79 | -477.17 | 4.29 | -207.25 | -69.74 | 2.72 | 8.69 | |
| EPS in Rs | 0.92 | 1.49 | 1.08 | 1.03 | 1.18 | 0.52 | 0.53 | -32.26 | 0.29 | -14.01 | -4.71 | 0.18 | 0.60 |
| Dividend Payout % | 106.01% | 65.88% | 92.37% | 155.17% | 85.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -65825% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -15% |
| 5 Years: | 20% |
| 3 Years: | -32% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -20% |
| 5 Years: | -21% |
| 3 Years: | -14% |
| 1 Year: | -54% |
| Return on Equity | |
|---|---|
| 10 Years: | -14% |
| 5 Years: | -60% |
| 3 Years: | -74% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.00 | 12.01 | 13.32 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 | 14.79 |
| Reserves | 304.24 | 306.70 | 504.69 | 754.74 | 747.66 | 751.03 | 760.28 | 283.65 | 287.98 | 80.62 | 10.98 | 13.69 | 16.88 |
| 0.00 | 72.77 | 0.00 | 0.00 | 0.00 | 3.85 | 0.00 | 2.39 | 1.82 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 8.80 | 22.35 | 16.03 | 7.15 | 11.81 | 6.62 | 11.20 | 10.94 | 14.11 | 23.77 | 5.90 | 1.57 | 1.43 | |
| Total Liabilities | 325.04 | 413.83 | 534.04 | 776.68 | 774.26 | 776.29 | 786.27 | 311.77 | 318.70 | 119.18 | 31.67 | 30.05 | 33.10 |
| 0.63 | 0.48 | 4.60 | 3.86 | 3.07 | 5.97 | 4.43 | 3.24 | 2.12 | 0.11 | 0.01 | 0.00 | 0.00 | |
| CWIP | 0.00 | 2.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 234.38 | 330.39 | 359.92 | 413.87 | 511.72 | 517.32 | 516.78 | 154.68 | 242.56 | 101.87 | 0.00 | 0.25 | 0.25 |
| 90.03 | 80.80 | 169.52 | 358.95 | 259.47 | 253.00 | 265.06 | 153.85 | 74.02 | 17.20 | 31.66 | 29.80 | 32.85 | |
| Total Assets | 325.04 | 413.83 | 534.04 | 776.68 | 774.26 | 776.29 | 786.27 | 311.77 | 318.70 | 119.18 | 31.67 | 30.05 | 33.10 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.55 | -10.77 | -32.96 | -24.02 | 12.91 | -14.91 | -2.66 | 32.58 | 26.89 | -4.48 | -19.51 | -0.62 | |
| 55.39 | -91.88 | -23.57 | -87.92 | -111.90 | 21.79 | 13.42 | -40.19 | -22.37 | -1.02 | 22.21 | -1.99 | |
| -11.96 | 60.53 | 57.88 | 239.40 | -28.45 | -8.26 | -0.25 | -1.11 | -0.84 | -0.23 | -0.04 | -0.29 | |
| Net Cash Flow | 40.87 | -42.12 | 1.36 | 127.46 | -127.44 | -1.38 | 10.51 | -8.72 | 3.69 | -5.73 | 2.66 | -2.91 |
| Free Cash Flow | -2.36 | -12.96 | -36.01 | -24.08 | 12.90 | -14.91 | -2.69 | 32.54 | 26.89 | -4.49 | -19.51 | -0.62 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -12% | -159% | 785% | 129% | -101% | 81% | 37% | -245% | 1,095% | 40% | 990% | 18% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 42.58 | 57.76 | 61.61 | 136.13 | 106.87 | 1,034.41 | 80.69 | 87.19 | 0.00 | 0.00 | 0.00 | |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 42.58 | 57.76 | 61.61 | 136.13 | 106.87 | 1,034.41 | 80.69 | 87.19 | 0.00 | 0.00 | 0.00 | |
| Working Capital Days | 394.32 | -731.70 | 1,958.48 | 26,942.68 | 3,456.03 | 33,992.29 | 7,838.99 | 1,844.47 | 241.86 | -1,163.02 | 5,410.11 | |
| ROCE % | 4.24% | 4.40% | 3.95% | 2.44% | 2.46% | 0.97% | -0.90% | 0.50% | 3.57% | -4.68% | 18.06% | 11.65% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Employee Headcount count |
|
||||||||||
| USA Revenue Share % |
|||||||||||
| Order Book USD million |
|||||||||||
| New Client Logos Added count |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement of the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- TAKE Limited reports H1 FY27 income of ₹615.54 million, PAT ₹32.75 million; launches TAKE.Health and ₹50 million innovation fund.
-
Board Meeting Outcome for Outcome Of The Board Meetine Held On Friday. November 13. 2026
- Board approved Q2 and H1 FY27 results; consolidated income Rs615.54 million, PAT Rs32.75 million.
- Financial Results For Quarter And Half Year Ended September 30, 2026
-
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company.
- Board to meet on November 13, 2026 to approve Q2 and half-year FY2026-27 financial results.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Aug 2021Transcript
-
Jun 2021Transcript
-
Feb 2021Transcript
-
Dec 2020Transcript
-
Sep 2020Transcript
-
Oct 2019Transcript
-
Aug 2019Transcript
-
May 2019Transcript
-
Mar 2019Transcript
-
Feb 2019Transcript
-
Feb 2019Transcript
-
Aug 2018Transcript
-
May 2018Transcript
-
Feb 2018Transcript
-
Nov 2017Transcript
-
Nov 2017Transcript
-
Aug 2017Transcript
-
May 2017Transcript
-
Jan 2017Transcript
-
Dec 2016Transcript
-
Oct 2016Transcript
-
Feb 2016PPT
Business Overview:[1]
Singapore-based TAKE Solutions Pte Limited holds a 52.90% stake in TSL, serving as the holding company. TSL specializes in Life Sciences and Supply Chain Management, providing comprehensive services in clinical development and specific offerings in supply chain. The company is involved in clinical trials, generics support, including bio-availability & bioequivalent studies, regulatory filing, and pharmacovigilance.